While Eli Lilly's Mounjaro and Zepbound offer better efficacy in clinical trials, but Novo Nordisk's Ozempic and Wegovy outpaces thanks to its superior marketing. Wegovy was reported deliver $2.54 ...

BioSpace reported that Eli Lilly faces fierce competition from Novo Nordisk (NYSE:NVO)'s Wegovy and Ozempic, which has led to lower-than-expected demand for Eli Lilly's weight loss and diabetes ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

However, these results roughly align with Lilly's Zepbound and fall short of its next-generation treatment, retatrutide, which showed up to 24% weight loss in mid-stage trials. Novo's stock has ...

and Eli Lilly's Zepbound (tirzepatide). The company has now launched a phase 2 trial of a once-monthly version of the drug, with results due in the first half of 2025. Meanwhile, it has taken ...

Eli Lilly declined 7.5% after the pharmaceutical company reported sales of blockbuster GLP-1 medicines Zepbound and Mounjaro that missed analysts’ estimates. Lilly said sales of Mounjaro ...

The U.S. drugmaker’s shares were up in Thursday trading. The stock has more than doubled in value in the last two years, ...

Zepbound (tirzepatide) is only available on prescription for people with obesity, or those with overweight. Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli ...

Walgreens reported fiscal first-quarter earnings and revenue that topped expectations, as it shutters stores and cuts other costs to steer itself out of a rough spot. The company capped off a ...

XRP continues its price rally on the back of rising whale activity and Ripple's legal milestones. A crypto trader dubs XRP an “alive monster,” forecasting a potential peak at $4.2. Get Wall ...

The Securities and Exchange Commission said it has settled charges against former World Wrestling Entertainment mogul Vince McMahon for allegedly violating federal securities laws by failing to ...